Similarly, in another randomized clinical trial by Akamatsu et al. [16], Osimertinib-plus-bevacizumab combination failed to show improvement of PFS in patients with advanced lung adenocarcinoma with EGFR T790M mutation when compared with Osimertinib alone [16]. The gene discussed is EGFR; the disease is lung adenocarcinoma.